Multiple Endocrine Neoplasia Type 1 Presenting with Hypoglycemia due to Insulinoma: A Case Report

Husain Taha Radhi1, Riyadh Almerbati, Ebthalib Al yusuf, Rawtha Fardan, Hasan Farooq and Saeed Khalaf

Department of Endocrinology, Salmanya Medical Complex, Ministry of Health, Bahrain

*Corresponding author: Husain Taha Radhi, Department of Endocrinology, Salmanya Medical Complex, Ministry of Health, Bahrain, E-mail: husaintaha74@yahoo.com

Received date: December 11, 2018; Accepted date: December 24, 2018; Published date: January 03, 2019

Keywords: Insulinoma; MEN1; Hypercalcemia; Hypoglycemia; Neuroendocrine tumor

Abstract

Multiple Endocrine neoplasia type 1 is a rare, autosomal dominant disorder consisting of tumors of the parathyroid, pancreatic islets, and anterior pituitary. The incidence of insulinoma in multiple endocrine neoplasia is relatively uncommon. However, insulinoma is the most common cause of hyperinsulinemic hypoglycemia. We report a case of a 38-year-old female who presented to the emergency department because of frequent attacks of hypoglycemia in the form of diaphoresis, loss of consciousness, and tonic-clonic seizures. Parathyroidectomy was performed for her when she was 10 years old. After the biochemical and radiological investigation, she has been diagnosed with Multiple Endocrine neoplasia type 1 due to the presence of insulinoma, parathyroid adenoma, and a pituitary microadenoma. Insulinoma is a rare condition, however it should be encountered in the differential diagnosis of any young individual presenting with frequent hypoglycemic symptoms.

Introduction

Multiple Endocrine neoplasia type 1 (MEN1) is a rare, autosomal dominant inherited endocrine disorder characterized by presentation of tumors of parathyroid glands, anterior pituitary, and pancreatic islet cells. MEN 1 is defined as the presence of two or more primary MEN tumor types, or occurrence of one of the MEN 1 associated tumor family members of a patient with clinical diagnosis of MEN 1 [1].

Insulinoma is a functional neuroendocrine tumor that secretes insulin. It may be associated with other endocrine glands tumors in the multiple endocrine neoplasia type 1 (MEN 1). It's the most common cause of hyperinsulinemic hypoglycemia and it's the second most common secreting pancreatic islets cell tumors associated with MEN1 after gastrinoma. Only 4-6% of patients with insulinoma will develop MEN1 [1,2]. Sporadic insulinoma usually develops after the age of 40, but MEN associated insulinoma usually occurs before the age of 40 and even sometimes before 20 [3].

We report a lady who was diagnosed with MEN1 upon her presentation with hypoglycemia.

Case Report

A 38-year-old female presented to the emergency department with loss of consciousness. She has experienced recurrent attacks of palpitation, sweating, tremor, light-headedness, seizure like movements and loss of consciousness for the past 6 months. She noticed that the symptoms disappeared after eating or ingestion of sugar. She denied taking any prescribed or over the counter medications. She didn't notice any change in her weight. She was referred previously to the psychiatrist, because of the unexplained loss of consciousness episodes and her treating physicians have cast doubt on the issue of intake of oral hypoglycemic agents by the patient. Parathyroidectomy was performed for her at the age of 10 years because of hypercalcemia, in which 3 parathyroid glands were removed and hyperplasia of the parathyroid glands were confirmed thereafter. However, her calcium level persisted to be at high levels. One of her sisters was operated for hyperparathyroidism in all her siblings and their children.

Physical examination revealed a well-nourished female. She weighed 63 kg with body mass index (BMI) of 24 kg/m². A horizontal old scar was found upon neck examination (Figure 1). Her abdomen was soft, and non-tender with no masses or organomegaly. Neurologic examination was normal.

Her blood glucose level was 35 mg/dL when she arrived at the emergency department. She was started on parenteral dextrose. Despite that she was receiving intravenous glucose, she continued to have hypoglycemia. Blood sample was drawn for insulin, C-peptide, cortisol, and glucose during the hypoglycemic attack. Results showed inappropriately normal insulin level and c-peptide in view of hypoglycemia. Physical examination revealed a well-nourished female. She weighed 63 kg with body mass index (BMI) of 24 kg/m². A horizontal old scar was found upon neck examination (Figure 1). Her abdomen was soft, and non-tender with no masses or organomegaly. Neurologic examination was normal.

Wound infection work up was conducted to rule out insulinoma as a cause of hyperinsulinemic hypoglycemia. Computed Tomography (CT) of the
abdomen revealed two well-defined, enhanced, lobulated pancreatic lesions, one was seen on the tail and measured 3.0 × 2.1 cm and the other one was seen in the body and measured 1.4 cm (Figure 3).

| Test      | Results | Reference Range | Unit  |
|-----------|---------|-----------------|-------|
| Insulin   | 15.5    | 2.6-37.6        | µIU/ML|
| C-peptide | 1.05    | 0.25-1.28       | nmol/L|
| Cortisol  | 85      | 193-690         | nmol/L|
| Glucose   | 2.5     | 3.6-8.9         | nmol/L|

**Table 1: Laboratory tests during hypoglycemia.**

| Test      | Results | Reference Range | Unit |
|-----------|---------|-----------------|------|
| ACTH      | 2.1     | <10.0           | pmol/L|
| Cortisol (zero time) | 71       | 193-690         | nmol/L|
| Cortisol (30 minutes) | 410     |                 | nmol/L|
| Cortisol (60 minutes) | 597     |                 | nmol/L|

**Table 2: Synacthen test.**

| Test | Results | Reference Range | Unit |
|------|---------|-----------------|------|
| Calcium | 2.63    | 2.15-2.5       | mmol/L|

**Table 3: Laboratory tests for hypercalcemia work up.**

| Test      | Results | Reference Range | Unit  |
|-----------|---------|-----------------|-------|
| Magnesium | 0.60    | 0.74-1.0        | mmol/L|
| Phosphorus| 1.0     | 0.81-1.45       | mmol/L|
| Albumin   | 39      | 35-52           | g/L   |

The patient underwent laparoscopic distal pancreatectomy. Histopathological evaluation of the pancreatic mass was consistent with insulinoma which stained positive for chromogranin (Figures 5-7). Immediately after removal of the mass blood glucose level increased to 136 mg/dL. She experienced no further hypoglycemic episodes postoperatively and the blood glucose levels were consistently in the normal range thereafter. She was discharged in a good health with proper glucose level. She was maintained on prednisolone 2.5 mg once daily. Follow up appointment at endocrine clinic was given.
Figure 3: Contrast enhanced CT abdomen is showing two well-defined, enhanced, loculated pancreatic lesions, one was seen on the tail and measured 3.0 × 2.1 cm and the other one was seen in the body and measured 1.4 cm which are highly suggestive of endocrine tumors.

Figure 4: MRI of the pituitary gland is showing a 5.7 mm left sided pituitary microadenoma.

CT findings were highly suggestive of endocrine tumors in particular insulinoma. Magnetic Resonance Imaging (MRI) of the pituitary revealed a 5.7 mm left sided pituitary microadenoma with centrally located pituitary stalk (Figure 4).

Figure 5: Low power magnification shows well circumscribed mass with gyriform pattern and patchy amyloid deposition (H&E 40x).

Figure 6: High power magnification shows neoplastic cells with salt-and-paper chromatin and mild nuclear pleomorphism. Amyloid deposition is noted (H&E 400x).
Discussion

MEN1 can be diagnosed clinically based on the presence of two or more MEN1-associated endocrine tumors [1]. A diagnosis of familial MEN1 is established in individuals with one of the MEN1-associated tumors who are first degree relatives of patients with a clinical diagnosis of MEN1. Genetic diagnosis of MEN1 is made in asymptomatic individuals and has not yet developed any of biochemical or radiological abnormalities indicative of tumor development but have germline MEN1 mutation [4]. Genetic study of MEN1 was not performed in our case because of the presence of insulinoma, parathyroid adenoma, and pituitary adenoma. Also, the family history of pancreatic tumor and hypercalcemia in her sister is highly suggestive of familial MEN1.

Parathyroid adenoma resulting in primary hyperparathyroidism is the most common feature of MEN1 and occurs in approximately 95% of MEN1 patients [5]. It is the earliest expression of MEN1. Primary hyperparathyroidism associated with MEN1 characterized by earlier age of onset compared with those without MEN1 (25-20 years vs. 55 years) [6]. That was consistent with our patient as her first presentation was at age of 10 years with hypercalcemia and parathyroid adenoma. We found many case reports which are in accordance with our case in showing that the earliest symptoms appeared between 5 and 11 years old [7,8]. In a large, multicenter MEN1 study published by Goudet et al. showed that first symptoms were related to hyperparathyroidism in 75% and insulinoma in 12% of the patients. The first symptoms occurred before 10 years old in 14% and before 5 years old in 3% [9].

10-60% of patients with MEN1 have pituitary tumors being prolactinoma the commonest tumor and the majorities are microadenoma. The mean age of onset of pituitary tumors in patients with MEN1 has been reported to be 38.0 ± 13.5 years [10]. Insulinoma represent 10 to 30% of all pancreatic tumors in patients with MEN1 [5] and they occur in patients with MEN1 who are younger than 40 years and many occur in individuals at younger than 20 [6].

Whether parathyroidectomy for our patient was a right decision to take at age of 10 years old is questionable, because persistent or recurrence hypercalcemia is found in 40-60% of adult patients within 1 to 12 years. Therefore, the timing of surgery and the right operation during the first two decades need to be reviewed in young MEN1 patients.

Surgical treatment of insulinoma has been found to be curative in many patients. The 5- and 10-year disease free survival rates are 100% and 96%, respectively [11]. Insulinomas with MEN1 has been reported to have higher risk of malignancy than insulinomas without MEN1. However most of the patients with insulinoma with MEN1 have achieved hypoglycemia-free status after the surgery [12]. Our patient was advised to have a regular follow up since MEN1 patients are prone to have recurrent tumors. Medical management has been used in unresectable metastatic tumors, inoperable patients, persistent symptoms after unsuccessful operation, and patients refusing surgery. Recent reported techniques for the management of insulinoma are injection of octreotide; EUS guided alcohol ablation, embolization, and radiofrequency ablation [2].

Cases of insulinoma remains undiagnosed for months or even years. In our patient, the duration of symptoms of hypoglycemia prior to diagnosis was 4 months. Other case reports showed that the mean duration of symptoms prior to diagnosis ranges from several months to several decades [13]. The reason behind that is that the symptoms are not unique to insulinoma, so a high index of suspicion is mandatory.

In Conclusion, this case reports MEN1 in a 38-year-old lady who presented with severe hypoglycemia as the manifestation of underlying insulinoma. Insulinoma is a rare, mostly benign tumor, but can be life-threatening by causing severe hypoglycemia. Insulinoma should always be considered in the differential diagnosis of all cases of non-diabetic hypoglycemia, since early detection and timely management could be lifesaving.

References

1. Thakker R, Newey P, Walls G, Bilezikian J, Dralle H, et al. (2012) Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J Clin Endocrinol Metab, 97: 2990-3011.
2. Okabayashi T, Shimo Y, Sumiyoshi T, Kozuki A, Ito S, et al. (2013) Diagnosis and management of insulinoma. World J Gastroenterol 19: 829-837.
3. Service F, Mcmahon M, O’Brien P, Ballard D (1991) Functioning Insulinoma—Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study. Mayo Clinic Proceedings 66: 711-719.
4. Turner J, Christie P, Pearce S, Turnpenny, P, Thakker R (2010) Diagnostic challenges due to phenocopies: lessons from Multiple Endocrine Neoplasia type I (MEN1). Human Mutation 31: 1089-1101.
5. Branzi M, Gagli V, Angeli A, Bilezikian J, Beck-Peccoz P, et al. (2001) CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2. J Clin Endocrinol Metab 86: 5658-5671.
6. Eller-Vainicher C, Chioldini I, Battista C, Viti R, Mascia M, et al. (2009) Sporadic and MEN1 related primary hyperparathyroidism: Differences in clinical presentation and severity. J Bone Miner Res 24: 1404-1410.
7. Shepherd J (1991) The Natural History of Multiple Endocrine Neoplasia Type 1. Archiv Surg 126: 935-952.
8. Trump D, Barren B, Wooding C, Pang J, Besser G, et al. (1996) Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 89: 653-670.
9. Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, et al. (2015) MEN1 Disease Occurring Before 21 Years Old: A 160-Patient Cohort Study From the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab 100: 1568-1577.
10. Verges B, Bourelle F, Goudet P, Murat A, Beckers A, et al. (2002) Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study. J Clin Endocrinol Metab 87: 457-465.
11. Crippa S, Zerbi A, Boninsegna L, Capitanio V, Partelli S, et al. (2012) Surgical Management of Insulinomas. Arch Surg 147: 261-266.
12. Verzosi D, Cardot-Bauters C, Boucaren N, Lebras M, Bertholon-Gregoire M, et al. (2015) Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d’étude des Tumeurs Endocrines (GTE) retrospective study. Eur J Endocrinol 172: 309-319.
13. Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas. Surg Clin North Am 81: 527-542.